Gestational diabetes mellitus
Related entities
Findings (50)
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
nullPregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.
Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85
None
improvementPregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and
Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97
None
improvementPregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and
Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97
None
improvementPregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and
Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97
None
improvementPregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and
Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97
None
improvementPregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and
Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97
None
improvementPregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and
Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97
None
improvementPregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and
Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97
None
improvementPregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and
Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97
None
improvementPregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and
Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97
None
improvementPregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and
Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97
None
improvementPregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and
Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97
None
improvementPregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and
Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97
None
improvementPregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and
Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97
None
improvementPregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and
Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97
None
improvementPregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and
Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97
None
improvementPregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and
Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97
None
improvementPregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and
Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97
None
improvementPregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and
Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97
None
improvementPregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and
Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97
None
improvementPregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and
Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97
None
improvementPregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and
Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97
None
improvementPregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and
Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97
None
improvementPregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and
Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97